Neothetics Fund Company Profile

Description

Neothetics, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients, as well as for the reduction of unwanted localized fat deposits under the chin or submental fat. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014. Neothetics, Inc. was founded in 2007 and is headquartered in San Diego, California.